Harlan Labs doubles in specialty research with U.S. expansion

Harlan Laboratories is investing heavily in its Indiana and California facilities, bolstering specialty research by more than doubling its number of isolators.

The expansion will help Harlan meet an increased demand for its immunocompromised research models, including mice, rats and other animals. Harlan said each new isolator boasts state-of-the-art equipment and biosecurity measures to keep samples pure and research models healthy.

"Our investment in these facilities underscores our commitment to providing the highest quality research models and services to investigators across the globe," Vice President Joe Meyer said in a statement. "We will continue to expand and enhance our facilities worldwide to meet the needs of the research community in key therapeutic research areas like oncology, immunology and toxicology with consistently dependable research models, diets and supporting services."

The two facilities have been revamped for sustainability, too, the company said, with energy-efficient lighting and watering systems that will keep the CRO's costs down while saving power.

Harlan's stateside expansion follows a $4.5 million investment in its Itingen, Switzerland, site last year, and the company has been working to expand its footprint around the globe, providing pre-clinical and non-clinical contract research for clients across biotech and other fields.

- read the announcement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.